Table of Contents
Ready to See Results?
From strategy through execution, Atlantic Health Strategies integrates compliance, operations, and growth into durable, measurable results. Let’s put our expertise to work for your organization.
The DSM Reset and Why It Matters for Outcomes
The short answer: the APA’s January 2026 roadmap pulls outcomes measurement inside the diagnostic frame itself. Functioning, quality of life, contextual factors, and biomarkers are no longer adjuncts payers bolt on. They are being proposed as part of the diagnosis. For behavioral health operators in Florida, Texas, and Arizona running multi-site models, that has direct consequences for documentation, utilization management, and payer contracting.
On January 28, 2026, the American Psychiatric Association published a series of papers from its Future DSM Strategic Committee outlining a new model for the manual. The five papers in The American Journal of Psychiatry describe plans to make the DSM a “truly living document” that responds to scientific developments faster than prior editions. The committee also proposed renaming the manual the Diagnostic and Scientific Manual of Mental Disorders, with no decision yet on whether it becomes DSM-6 or something else.
The DSM is not just a clinical reference. It sits underneath diagnosis, reimbursement, utilization management, quality reporting, and population health analytics. When the APA changes the architecture, the downstream reporting that SAMHSA, CMS, state Medicaid agencies, and commercial payers depend on changes with it.
From Symptom Checklists to Functional Outcomes
One subcommittee under the Future DSM Strategic Committee was created specifically to address quality of life and functioning as part of the diagnostic structure, alongside subcommittees on biomarkers, structure and dimensions, and social determinants. That is a real departure from symptom thresholds and duration criteria as the primary diagnostic anchor.
This aligns with where CMS is already going. CMS has set a goal of having 100% of original Medicare beneficiaries and the majority of Medicaid beneficiaries in accountable care relationships by 2030. Commercial payers are tracking the same direction. UnitedHealthcare, Humana, Centene, Cigna, and CVS Health have already pledged to align payment arrangements with the CMS ACCESS model, which centers on measurement-based care and population attribution.
Operators who treat PHQ-9 and GAD-7 scores as a clinical nicety are about to learn they were always a billing asset. CPT 96127 already pays roughly $15 to $25 per administration of a validated brief assessment. Multiply that across a Level 2.5 partial hospitalization census of 40 patients with twice-weekly assessments, and the revenue and the audit exposure both compound quickly.
The harder problem: fewer than 20% of clinicians consistently use measurement-based care, despite endorsements from SAMHSA, APA, CMS, and NCQA. AHS sees this gap in nearly every operational assessment we conduct: tools exist in the EMR, but clinical leadership has not built the workflows that make scores reliable, time-stamped, and tied to level-of-care decisions under the ASAM Criteria, 4th Edition.
Contextual Determinants and Equity-Oriented Measurement
Another pillar of the roadmap is the formal integration of socioeconomic, cultural, and environmental determinants of mental health. The APA’s Socioeconomic, Cultural, and Environmental Determinants of Mental Health Subcommittee was created to determine how these factors get measured and documented in clinical assessment, and how they should shape diagnosis and treatment across diverse contexts.
That subcommittee was direct about the biggest operational obstacle. It identified data as the largest challenge, noting that many health systems and providers do not routinely collect SCE-DoH data by race, ethnicity, gender, or other key demographic and exposure variables. For executive teams at multi-site treatment organizations, that is a documented warning about where audits will land next.
The volume problem is real. SAMHSA’s 2023 NSDUH found that 58.7 million U.S. Adults (22.8%) had any mental illness in the past year, and among the 48.5 million people aged 12 or older with a substance use disorder in 2023, only 15.6% received treatment. A treatment system serving high-acuity, under-resourced populations cannot be benchmarked against one serving low-acuity commercial census without contextual adjustment. The current DSM does not force that adjustment. The proposed framework does.
Operators in Florida, Tennessee, and Ohio should be preparing data governance now. Social determinants captured as unstructured narrative in clinical notes are not auditable, not reportable to a payer’s SIU on request, and not usable for risk adjustment.
Biomarkers, Dimensional Models, and Measurement Complexity
The roadmap also opens the door to biological markers and dimensional constructs. Future DSM Strategic Committee chair Maria Oquendo, MD, PhD, described a four-domain model: contextual factors, diagnoses, biomarkers and biological factors, and transdiagnostic features. Nitin Gogtay, MD, vice-chair of the committee, framed the rationale this way: “we are envisioning is a living DSM, a scientifically authoritative resource that is updated in a structured, deliberate manner as the new evidence becomes available.”
Operators should read that carefully. A continuously updated diagnostic framework introduces version control problems that the current model never had. Today, a treatment center’s UR team works against DSM-5-TR (published 2022). Under a living-document model, the criteria a clinician documented against in Q1 may not be the criteria a payer audits against in Q4. That is a contracting problem, a documentation training problem, and a denial-management problem all at once.
For organizations participating in risk-based contracts, measurement systems must remain stable enough to support longitudinal analysis. CEOs and clinical leadership teams will need to decide which new data streams add operational and clinical value versus which add noise, cost, and compliance risk.
Strategic Implications for CEOs and Health System Leaders
This is not an academic exercise. APA CEO and Medical Director Marketa Wills, MD, MBA, said “the goal is to advance scientific rigor, cultural inclusivity, and adaptability while ensuring that the DSM remains useful to clinicians and remains a trusted, relevant tool.” The downstream effect is that diagnosis and outcomes measurement begin to converge inside the same architecture.
CEOs running behavioral health organizations should be doing four things now. First, audit your EMR’s capacity to capture functional and quality-of-life data as structured fields, not narrative. Second, align documentation training with both the ASAM Criteria, 4th Edition for level-of-care decisions and current DSM-5-TR criteria for diagnosis, while watching the APA’s continuous-update channel. Third, treat social determinants data as a regulated data category with governance, retention, and access controls, not a clinical curiosity. Fourth, model what a measurement-based-care workflow costs and produces at each level of care you operate, from Level 3.7 medically-monitored intensive inpatient down through Level 2.5 partial hospitalization and Level 1 outpatient.
The organizations that treat DSM modernization as a documentation problem will be the ones whose UR denials climb in 2027 and 2028. The ones that treat it as an operational redesign will own a defensible payer position when commercial contracts and CMS models start pricing outcomes directly. AHS works with executive teams on exactly that redesign, and we would rather have the conversation eighteen months early than eighteen months late.
Frequently asked questions
When will the next DSM be released, and what should operators do in the meantime?
The APA has not announced a publication date. On January 28, 2026, the Future DSM Strategic Committee published its roadmap in The American Journal of Psychiatry and proposed a continuous-update ‘living document’ model rather than a single dated edition. DSM-5-TR (published 2022) remains the working manual. Operators should keep documentation aligned to DSM-5-TR today while building governance to absorb continuous updates.
How does DSM modernization affect payer audits and utilization management?
Functional status, quality of life, and contextual factors are being proposed as part of the diagnostic structure itself, not as external overlays. That means UM reviewers and SIU auditors will increasingly expect those data points to be structured and time-stamped in the chart. CMS has stated a goal of moving 100% of original Medicare beneficiaries and the majority of Medicaid beneficiaries into accountable care relationships by 2030, and commercial payers including UnitedHealthcare, Humana, Centene, Cigna, and CVS Health have aligned with the CMS ACCESS model’s measurement-based-care approach.
What is the gap between what payers expect and what providers actually do on measurement-based care?
Wide. Fewer than 20% of clinicians consistently use measurement-based care, despite endorsements from SAMHSA, APA, CMS, and NCQA. That gap is a documentation risk under current DSM-5-TR contracts and becomes a contracting risk under the future DSM model.
Does this affect ASAM level-of-care decisions for SUD treatment?
Indirectly, yes. DSM provides the diagnostic substrate; the ASAM Criteria, 4th Edition govern level-of-care placement across Level 1 outpatient, Level 2.1 intensive outpatient, Level 2.5 partial hospitalization, Level 3.x residential, and Level 3.7 medically-monitored intensive inpatient. As DSM begins to incorporate functioning and contextual factors directly into diagnosis, the data feeding ASAM dimensional assessments will need to be cleaner, structured, and consistent across episodes of care.
References
- American Psychiatric Association. APA Releases Roadmap for the Future of the DSM (January 28, 2026)
- Medscape Medical News. What Will the Next DSM Look Like?
- Psychiatric Times. A New and Improved DSM? APA Shares Strategy and Roadmap
- American Journal of Psychiatry. The Future of DSM: Socioeconomic, Cultural, and Environmental Determinants and Intersectionality
- SAMHSA. 2023 National Survey on Drug Use and Health (NSDUH) Annual National Report
- Meadows Mental Health Policy Institute. Increasing Measurement-Based Assessment and Care
- Behavioral Health Business. Early Participants of CMS ACCESS Model See Program as Accelerant for Value-Based Care
- American Psychiatric Association. About DSM-5-TR